4.6 Review

Multiple Endocrine Neoplasia Type 1: Latest Insights

Journal

ENDOCRINE REVIEWS
Volume 42, Issue 2, Pages 133-170

Publisher

ENDOCRINE SOC
DOI: 10.1210/endrev/bnaa031

Keywords

MEN1; phenocopy; menin; mutation-negative; neuroendocrine tumors; epigenetics; mouse models; pharmacological therapies; surgical approaches; quality of life

Funding

  1. FIRMO Foundation
  2. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
  3. NIHR Oxford Biomedical Research Centre Programme

Ask authors/readers for more resources

MEN1 syndrome is a rare hereditary tumor syndrome that involves multiple fields such as endocrinology, gastroenterology, surgery, radiology, genetics, and molecular biology. Research findings have contributed to understanding the pathogenesis of MEN1-associated tumors and developing new treatment methods, as well as improving the diagnosis and management of MEN1-related diseases.
Multiple endocrine neoplasia type 1 (MEN1), a rare tumor syndrome that is inherited in an autosomal dominant pattern, is continuing to raise great interest for endocrinology, gastroenterology, surgery, radiology, genetics, and molecular biology specialists. There have been 2 major clinical practice guidance papers published in the past 2 decades, with the most recent published 8 years ago. Since then, several new insights on the basic biology and clinical features of MEN1 have appeared in the literature, and those data are discussed in this review. The genetic and molecular interactions of the MEN1-encoded protein menin with transcription factors and chromatin-modifying proteins in cell signaling pathways mediated by transforming growth factor beta/bone morphogenetic protein, a few nuclear receptors, Wnt/beta-catenin, and Hedgehog, and preclinical studies in mouse models have facilitated the understanding of the pathogenesis of MEN1-associated tumors and potential pharmacological interventions. The advancements in genetic diagnosis have offered a chance to recognize MEN1-related conditions in germline MEN1 mutation-negative patients. There is rapidly accumulating knowledge about clinical presentation in children, adolescents, and pregnancy that is translatable into the management of these very fragile patients. The discoveries about the genetic and molecular signatures of sporadic neuroendocrine tumors support the development of clinical trials with novel targeted therapies, along with advancements in diagnostic tools and surgical approaches. Finally, quality of life studies in patients affected by MEN1 and related conditions represent an effort necessary to develop a pharmacoeconomic interpretation of the problem. Because advances are being made both broadly and in focused areas, this timely review presents and discusses those studies collectively.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available